Covid-19: Sensorion delays Phase ll trial due to slow recruitment rate
SENS-401 is a drug candidate intended for the protection of inner ear tissue from damages that can lead to progressive or sequelar hearing impairment. Credit: Travis Isaacs.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more